EGFR and lung carcinoma: We can note that in a retrospective cohort study of 239 patients, an SRT approach led to an OS improvement compared to a WBRT approach in a population of patients presenting metastatic EGFR-mutated lung cancer with BM (HR = 0.38, 95% CI 0.17–0.84, p = 0.017) [33].